- Mog (35-55)
-
- $1.00
-
2026-10-29
- CAS:149635-73-4
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 100kg
- ACTH (1-14)
-
-
2026-10-29
- CAS:149635-73-4
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 20 tons
|
| | Mog (35-55) Basic information |
| Product Name: | Mog (35-55) | | Synonyms: | H-MET-GLU-VAL-GLY-TRP-TYR-ARG-SER-PRO-PHE-SER-ARG-VAL-VAL-HIS-LEU-TYR-ARG-ASN-GLY-LYS-OH;H-MET-GLU-VAL-GLY-TRP-TYR-ARG-SER-PRO-PHE-SER-ARG-VAL-VAL-HIS-LEU-TYR-ARG-ASN-GLY-LYS-OH (MOUSE, RAT);MET-GLU-VAL-GLY-TRP-TYR-ARG-SER-PRO-PHE-SER-ARG-VAL-VAL-HIS-LEU-TYR-ARG-ASN-GLY-LYS;MEVGWYRSPFSRVVHLYRNGK;MK21;H-MEVGWYRSPFSRVVHLYRNGK-OH;MET-GLU-VAL-GLY-TRP-TYR-ARG-PRO-PRO-PHE-SER-ARG-VAL-VAL-HIS-LEU-TYR-ARG-ASN-GLY-LYS;MET-GLU-VAL-GLY-TRP-TYR-ARG-SER-PRO-PHE-SER-ARG-VAL-VAL-HIS-LEU-TYR-ARG-ASN-GLY-LYS: MEVGWYRSPFSRVVHLYRNGK | | CAS: | 149635-73-4 | | MF: | C118H177N35O29S | | MW: | 2581.95 | | EINECS: | 251-228-4 | | Product Categories: | peptide;Various Peptides | | Mol File: | 149635-73-4.mol |  |
| | Mog (35-55) Chemical Properties |
| density | 1.48±0.1 g/cm3(Predicted) | | storage temp. | -15°C | | solubility | ≥32.25 mg/mL in H2O; insoluble in EtOH; ≥86 mg/mL in DMSO | | form | solid | | color | White to off-white | | Water Solubility | Soluble to 0.50 mg/ml in water | | Sequence | H-Met-Glu-Val-Gly-Trp-Tyr-Arg-Ser-Pro-Phe-Ser-Arg-Val-VAL-His-Leu-Tyr-Arg-Asn-Gly-Lys-OH | | InChIKey | JMTCEFUSRHYJBF-LTFOILMJNA-N |
| | Mog (35-55) Usage And Synthesis |
| Description | MOG (35-55) or myelin oligodendrocyte glycoprotein (MOG) 35-55 is a minor component of CNS myelin. MOG (35-55) produces a relapsing-remitting neurological disease with extensive plaque-like demyelination, common to the manifestations of multiple sclerosis. MOG (35-55) induces strong T and B cell responses and is highly encephalitogenic. MOG (35-55) induces T cell-mediated multiple sclerosis in animal models. When co-administered with ITE, MOG (35-55) induces tolerogenic dendritic cells and suppresses disease development in mouse preclinical models of multiple sclerosis. | | Uses | Mog (35-55) can be used as an antigen immunized C57BL/6J mice to induces severe chronic experimental autoimmune encephalomyelitis in transgenic mice. | | Biological Activity | mog (35-55) is a truncated peptide derived from the human myelin oligodendrocyte glycoprotein (mog). mog, a member of the immunoglobulin superfamily, is expressed wildly in the central nervous system. in mouse and rat models for human multiple sclerosis, mog is involved in inducing the experimental autoimmune encephalomyelitis. humoral auto-immunity to the myelin oligodendrocyte glycoprotein (mog) may be associated with the pathogenesis of multiple sclerosis (ms) [1].mog (35-55) is involved in inducing autoantibody production and relapsing-remitting neurological disease causing extensive plaque-like demyelination [2]. in hla-dr2-transgenic mice, myelin oligodendrocyte glycoprotein-35-55 peptide induced severe chronic experimental autoimmune encephalomyelitis [3].mog35-55 was highly encephalitogenic and could induce strong t and b cell responses in rats [4]. in nod/lt mice (h-2g7) and c57bl/6 mice (h-2b), single injection of mog35-55 in cfa could induce ms-like disease [4]. | | in vivo | Myelin oligodendrocyte glycoprotein (MOG) peptide 35-55 is one of the targets of self-reactive T cell responses, leading to acute and later chronic autoimmune processes. MOG 35-55 is capable of inducing experimental autoimmune encephalomyelitis (EAE) in B6 mice[1].
Induction of experimental autoimmune encephalomyelitis (EAE) model[3] Background
Myelin Oligodendrocyte Glycoprotein Peptide (35-55) CAN trigger an immune response against the CNS, and induces inflammation and destruction of myelin or antigen-bearing structures that causes neurological abnormalities.
Specific Modeling Methods
Mice: C57BL/6 background mice 2-4 months old male and female
Administration: On day 0: 3 mg/mL peptide plus CFA (4 mg/mL) Mix thoroughly 1: 1 peptide and CFA solutions s.c. 100 μL for each hind flank; On day 0 and day 2: 2.5 μg/mL of Bordetella pertussis toxin i.p. 200 μL
Note
1. Once peptide and CFA emulsion is formed, it can be stored at 4 °C for a few hours or used immediately.
2. Symptoms appear approximately 10-15 days after immunization.
3. When mice have clinical symptoms of EAE, hydrated food is placed on the cage floor to facilitate access to these mice.
4. Record parameters every other day at the beginning, and daily from 7th postimmunization day. Body weight decreases usually precedes EAE clinical signs and is a very objective and
valuable measure.
Modeling Indicators Evaluate changes in body weight and clinical scoring: body weight loss, loss of tail tonus, paralyzed tail, hind limb paraparesis, hind limb paralysis, front leg paralysis, tetraplegia, moribund, etc.
prototypical histopathological changes: Luxol fast blue staining of spinal cord for myelin evaluation shows infiltrates and demyelination in EAE animals.
Correlated Product(s): Complete Freund's adjuvant (CFA) (HY-153808) Opposite Product(s): / | Animal Model: | HLA-DR2 (DRB1*1501) mice[1] | | Dosage: | 200 μg (0.2 mL) | | Administration: | Intraperitoneal injection; once, for 38 days | | Result: | Resulted in paralysis of both hind and forelimbs. |
| | storage | Store at -20°C | | references | [1]. de march a k, de bouwerie m, kolopp-sarda m n, et al. anti-myelin oligodendrocyte glycoprotein b-cell responses in multiple sclerosis[j]. journal of neuroimmunology, 2003, 135(1): 117-125.
[2]. slavin a, ewing c, liu j, et al. induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein[j]. autoimmunity, 1998, 28(2): 109-120.
[3]. rich c, link j m, zamora a, et al. myelin oligodendrocyte glycoprotein‐35–55 peptide induces severe chronic experimental autoimmune encephalomyelitis in hla‐dr2‐transgenic mice[j]. european journal of immunology, 2004, 34(5): 1251-1261.
[4]. slavin a, ewing c, liu j, et al. induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein[j]. autoimmunity, 1998, 28(2): 109-120. |
| | Mog (35-55) Preparation Products And Raw materials |
|